Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P49247

UPID:
RPIA_HUMAN

ALTERNATIVE NAMES:
Phosphoriboisomerase

ALTERNATIVE UPACC:
P49247; Q541P9; Q96BJ6

BACKGROUND:
The enzyme Ribose-5-phosphate isomerase, alternatively known as Phosphoriboisomerase, is pivotal in the pentose phosphate pathway, facilitating the conversion between ribose-5-phosphate and ribulose 5-phosphate. This conversion is essential for the synthesis of nucleotides, highlighting the enzyme's critical role in cellular metabolism and genetic material production.

THERAPEUTIC SIGNIFICANCE:
Ribose 5-phosphate isomerase deficiency, associated with mutations in the enzyme's gene, manifests as leukoencephalopathy and psychomotor issues. The exploration of Ribose-5-phosphate isomerase's function offers promising avenues for developing treatments for this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.